Piper Sandler Maintains Overweight on LENZ Therapeutics, Raises Price Target to $51

Benzinga · 6d ago
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and raises the price target from $38 to $51.